BioSpace News Archive

As positivity rates surge across the country, and public health officials worry about the supply of COVID tests, Vault Health stands ready to meet the country’s need for COVID testing.

Second Genome today announced that the U.S. Patent and Trademark Office issued a U.S. patent, No. 11,174,293 B2, entitled, “Proteins for the Treatment of Epithelial Barrier Function Disorders.”

Harrow Health, Inc. today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic medicines, IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis.

Vesper Medical, Inc. today announced the completion of enrollment in its pivotal study - Venous stent for the Iliofemoral Vein Investigational clinical trial using the Vesper DUO Venous Stent System® (VIVID).i

Alnylam Pharmaceuticals, Inc. announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1/2 study of ALN-XDH, an investigational RNAi therapeutic targeting xanthine dehydrogenase (XDH) for the treatment of gout.

Mednow Inc. is pleased to announce the Company will be hosting its quarterly conference call on Wednesday December 22, 2021 at 8:30am EST.

GBS today announced that Dr. Steven Boyages, GBS’ interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings.

KemPharm, Inc. announced today its Board of Directors has authorized a program to repurchase up to $50 million of the Company’s outstanding stock.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced regulatory updates for its lead drug candidate, repotrectinib, a ROS1/TRK Inhibitor, and for elzovantinib (TPX-0022), its drug candidate targeting MET, CSF1R and SRC.

Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agency (EMA) for FINTEPLA® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a highly treatment-resistant form of childhood-onset epilepsy.